330975-13-8

Basic information

• Product Name: 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI)
• Synonyms: 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI);trans-4-aminotetrahydro-3-furanol(SALTDATA: HCl);(3R,4S)-4-aMinotetrahydrofuran-3-ol
• CAS NO: 330975-13-8
• Molecular Formula: C4H9NO2
• Molecular Weight: 103.12
• Product Categories: VARIOUSAMINE
• Mol File: 330975-13-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI)(330975-13-8)
• EPA Substance Registry System: 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI)(330975-13-8)

Safety Data

• Hazardous Substances Data: 330975-13-8(Hazardous Substances Data)

Usage

Uses

Since the provided materials do not specify the uses of 3-Furanol,4-aminotetrahydro-,(3R,4S)-rel-(9CI), it is not possible to list its applications based on the information given. However, based on the structural features of the compound, one can hypothesize potential uses in various industries, such as pharmaceuticals, materials science, or chemical research. To provide a detailed list of uses, additional information or research would be required.

Upstream product

• 285-69-8 3,4-epoxytetrahydrofuran 
• 153610-13-0 (3S,4R)-4-Azido-tetrahydro-furan-3-ol 
• 1430230-65-1 (3R,4S)-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 1430230-65-1 (3S,4S)-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 183184-50-1 trans-4-azido-3-hydroxytetrahydrofuran 
• 190792-68-8 [(3R,4S)-4-azidotetrahydrofuran-3-yl]oxytrimethylsilane 

Downstream Products

• 1430230-65-1 (±)-trans-3-tert-butoxycarbonylamino-4-hydroxytetrahydrofuran 
• 1430230-65-1 tert-butyl 4-hydroxytetrahydrofuran-3-ylcarbamate 
• 1421766-35-9 C₁₇H₁₈Cl₂N₄O₄ 
• 1421582-96-8 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1421583-08-5 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 215940-74-2 [(S)-1-((3S,4R)-4-Hydroxy-tetrahydro-furan-3-ylcarbamoyl)-3-methyl-butyl]-carbamic acid benzyl ester 
• 5834-36-6 3-oxa-6-azabicyclo[3.1.0]hexane 
• 1421582-94-6 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1421582-95-7 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3R,4S)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1421582-97-9 4-(5-{(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl}-1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide 
• 1430230-65-1 tert-butyl ((3S,4R)-4-hydroxytetrahydrofuran-3-yl)carbamate 

Relevant articles and documents

SALT FORM AND CRYSTAL FORM OF COMPOUND AS FGFR4 INHIBITOR AND PREPARATION METHOD THEREOF

The present invention provides a salt form, a crystal form, and a preparation method of a compound as an FGFR4 inhibitor and medical uses thereof.

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF

Provided are a class of compounds as shown in formula (I) as FGFR4 inhibitors, and pharmaceutically acceptable salts thereof, preparation methods therefor and the use thereof in the preparation of drugs for treating FGFR4-related diseases.

NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF

There is provided a morpholine derivative represented by General Formula [1A] or a salt thereof. (In the formula, a ring A represents a ring represented by General Formula [I]; * represents a bonding position; Z2 represents CH or the like; Z1 represents CR6 or the like; R6 represents a hydrogen atom or the like; X1 represents CHR7 or the like; R7 represents a hydrogen atom or the like; X2 represents CH2 or the like; R1 and R2 are the same as or different from each other, and each of R1 and R2 represents a hydrogen atom or the like; R3, R4, and R5 are the same as or different from each other, and each of R3, R4, and R5 represents a hydrogen atom, NRaRb, or the like; and each of Ra and Rb represents a hydrogen atom, a C1-8 alkyl group which may have a substituent, or the like.)

SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE

Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention relates to compounds useful as inhibitors of protein kinases, containing a cysteine residue in the ATP binding site. The invention further provides for pharmaceutically acceptable compositions comprising therapeutically effective amounts of one or more of the protein kinase inhibitor compounds and methods of using said compositions in the treatment of cancers and carcinomas.

Enzymatic preparation of cis and trans-3-amino-4-hydroxytetrahydrofurans and cis-3-amino-4-hydroxypyrrolidines

The lipase catalyzed resolution of cis and trans-3-amino-4-hydroxytetrahydrofurans and cis-3-amino-4-hydroxypyrrolidines have been studied. For all the heterocycles, the best enantioselectivity was obtained using Candida antarctica lipases A and B as cata

SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention provides novel selective androgen receptor modulators and their salts and pharmaceutical compositions thereof.

NOVEL TRIAZINE COMPOUNDS

The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.

Enantioselective ring-opening of aziridines

A process for the preparation of a nucleophilic addition product of an aziridine and a nucleophile, the process comprising treating the arizidine with the nucleophile in the presence of a biaryl phosphoric acid catalyst